FANCM missense variants and breast cancer risk: a case-control association study of 75,156 European womenGisella Figlioli, Montserrat García‐Closas, Amandine Billaud et al.|European Journal of Human Genetics|2023Cited by 14
Impact of Prosigna test on adjuvant treatment decision in lymph node-negative early breast cancer—a prospective national multicentre study (EMIT-1)Hege O. Ohnstad, Bjørn Naume, Elin Borgen et al.|ESMO Open|2024Cited by 14
Cost-effectiveness of Prosigna for Adjuvant Treatment Decisions in Early Breast Cancer: Healthcare Sector and Societal PerspectivesLars Asphaug, Bjørn Naume, Lars A. Akslen et al.|Clinical Breast Cancer|2025Cited by 2